22 May 2024
22 May 2024
Genmab has gained access to ProfoundBio’s ADCs for cancer treatment.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
Aktis will receive $60m in an upfront payment from Lilly, with the biotech eligible for up to $1.1bn in milestone payments and royalties.
Alvotech is eligible to receive undisclosed upfront and milestone payments for the biosimilar candidate.
Roche announced an FDA breakthrough therapy designation for its inavolisib / Ibrance combination therapy.
As the 2024 US Election begins to pick up steam, the Biden administration is already trying to remind voters of past success while challenging healthcare pricing.
The three companies will develop custom solutions throughout the drug development lifecycle.
Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
